241 related articles for article (PubMed ID: 35184426)
1. Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development.
Kim HW; Yoon EJ; Jeong SH; Park MC
Yonsei Med J; 2022 Mar; 63(3):241-251. PubMed ID: 35184426
[TBL] [Abstract][Full Text] [Related]
2. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
3. The impact of short-chain fatty acid-producing bacteria of the gut microbiota in hyperuricemia and gout diagnosis.
Martínez-Nava GA; Méndez-Salazar EO; Vázquez-Mellado J; Zamudio-Cuevas Y; Francisco-Balderas A; Martínez-Flores K; Fernández-Torres J; Lozada-Pérez C; Guido-Gómora DL; Martínez-Gómez LE; Jiménez-Gutiérrez GE; Pineda C; Silveira LH; Sánchez-Chapul L; Sánchez-Sánchez R; Camacho-Rea MDC; Martínez-Armenta C; Burguete-García AI; Orbe-Orihuela C; Lagunas-Martínez A; Palacios-González B; López-Reyes A
Clin Rheumatol; 2023 Jan; 42(1):203-214. PubMed ID: 36201123
[TBL] [Abstract][Full Text] [Related]
4. Altered Gut Microbiota in Children With Hyperuricemia.
Yuan X; Chen R; Zhang Y; Lin X; Yang X
Front Endocrinol (Lausanne); 2022; 13():848715. PubMed ID: 35574004
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
[TBL] [Abstract][Full Text] [Related]
6. Hmong microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C): A phase II clinical study protocol.
Wen YF; Culhane-Pera KA; Pergament SL; Moua Y; Vue B; Yang T; Lo M; Sun B; Knights D; Straka RJ
PLoS One; 2023; 18(2):e0279830. PubMed ID: 36724193
[TBL] [Abstract][Full Text] [Related]
7. Characteristic alterations of gut microbiota in uncontrolled gout.
Ul-Haq A; Lee KA; Seo H; Kim S; Jo S; Ko KM; Moon SJ; Kim YS; Choi JR; Song HY; Kim HS
J Microbiol; 2022 Dec; 60(12):1178-1190. PubMed ID: 36422845
[TBL] [Abstract][Full Text] [Related]
8. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis.
Luo Y; Song Q; Li J; Fu S; Yu W; Shao X; Li J; Huang Y; Chen J; Tang Y
BMC Nephrol; 2024 Feb; 25(1):63. PubMed ID: 38395818
[TBL] [Abstract][Full Text] [Related]
9. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
11. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
12. Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
Kvasnička A; Friedecký D; Brumarová R; Pavlíková M; Pavelcová K; Mašínová J; Hasíková L; Závada J; Pavelka K; Ješina P; Stibůrková B
Arthritis Res Ther; 2023 Dec; 25(1):234. PubMed ID: 38042879
[TBL] [Abstract][Full Text] [Related]
13. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
15. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
Hakoda M; Kasagi F
Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
[No Abstract] [Full Text] [Related]
16. Alteration of Gut Microbiome and Correlated Amino Acid Metabolism Contribute to Hyperuricemia and Th17-Driven Inflammation in
Song S; Lou Y; Mao Y; Wen X; Fan M; He Z; Shen Y; Wen C; Shao T
Front Immunol; 2022; 13():804306. PubMed ID: 35197978
[TBL] [Abstract][Full Text] [Related]
17. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
Zhang X; Tang Y; Wang M; Wang D; Li Q
Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout.
Wang Z; Li Y; Liao W; Huang J; Liu Y; Li Z; Tang J
Front Cell Infect Microbiol; 2022; 12():935723. PubMed ID: 36034697
[TBL] [Abstract][Full Text] [Related]
19. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
[TBL] [Abstract][Full Text] [Related]
20. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Levy GD; Rashid N; Niu F; Cheetham TC
J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
